Literature DB >> 8475539

Prolonging discordant xenograft survival with anticomplement reagents K76COOH and FUT175.

S Miyagawa1, R Shirakura, G Matsumiya, N Fukushima, S Nakata, H Matsuda, M Matsumoto, H Kitamura, T Seya.   

Abstract

The guinea pig heart, when transplanted into the rat heterotopically, is rejected within 30 min via activation of the alternative complement pathway. Natural antibody does not contribute to rejection. This xenotransplantation model was used to assess the effect of anti-complement reagents on discordant xenograft survival. In vivo administration of K76COOH (K76) to rats induced only slight suppression of factors B and D and a marked decrease of C3, leading to the depression of ACH50 (reflecting the potency of the alternative pathway). On the other hand, FUT175 (FUT) reduced C3 activity by about 80% and inhibited factor B activity nearly 100% < 1 hr after the administration, but inhibited factor D activity only marginally. FUT abrogated ACH50 for > 6 hr. Of note, the xenograft beating time was prolonged approximately 3 times by FUT but not by K76, suggesting that direct inhibition of plasma serine protease factor B results in the complete suppression of ACH50 and graft survival. The administration of both K76 and FUT resulted in the longest graft survival, but the effects of these reagents were abolished by additional antigraft antibody. Anticomplement reagents that block factor B and C3 are therefore effective for prolongation of discordant xenograft survival when the graft rejection is associated with the complement alternative pathway.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8475539     DOI: 10.1097/00007890-199304000-00004

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  13 in total

1.  Clinical xenotransplantation.

Authors:  Thomas E Starzl; Noriko Murase; Andreas Tzakis; John J Fung; Satoru Todo; Anthony J Demetris; Rafael Manez; Ignazio R Marino; Luis Valdivia
Journal:  Xenotransplantation       Date:  1994-08       Impact factor: 3.907

2.  Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience.

Authors:  K Abu-Elmagd; S Todo; J Fung; J Demetris; J Rakela; A S Rao; S Iwatsuki; T Starzl
Journal:  Clin Transpl       Date:  1994

Review 3.  The future use of complement inhibitors for the treatment of neurological diseases.

Authors:  E G McGeer; P L McGeer
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

4.  Cytokine-induced neutrophil chemoattractant in a rat model of lipopolysaccharide-induced acute lung injury.

Authors:  H Yamasawa; Y Ishii; S Kitamura
Journal:  Inflammation       Date:  1999-06       Impact factor: 4.092

Review 5.  The biological basis of and strategies for clinical xenotransplantation.

Authors:  T E Starzl; L A Valdivia; N Murase; A J Demetris; P Fontes; A S Rao; R Manez; I R Marino; S Todo; A W Thomson
Journal:  Immunol Rev       Date:  1994-10       Impact factor: 12.988

Review 6.  Prospects of clinical xenotransplantation.

Authors:  T E Starzl; A Tzakis; J J Fung; S Todo; A J Demetris; R Manez; I R Marino; L Valdivia; N Murase
Journal:  Transplant Proc       Date:  1994-06       Impact factor: 1.066

7.  Near completely humanized liver in mice shows human-type metabolic responses to drugs.

Authors:  Chise Tateno; Yasumi Yoshizane; Naomi Saito; Miho Kataoka; Rie Utoh; Chihiro Yamasaki; Asato Tachibana; Yoshinori Soeno; Kinji Asahina; Hiroshi Hino; Toshimasa Asahara; Tsuyoshi Yokoi; Toshinori Furukawa; Katsutoshi Yoshizato
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

8.  Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation.

Authors:  M Tanaka; N Murase; Q Ye; W Miyazaki; M Nomoto; H Miyazawa; R Manez; Y Toyama; A J Demetris; S Todo; T E Starzl
Journal:  Transplantation       Date:  1996-09-15       Impact factor: 4.939

Review 9.  Clinical trials and projected future of liver xenotransplantation.

Authors:  J Fung; A Rao; T Starzl
Journal:  World J Surg       Date:  1997 Nov-Dec       Impact factor: 3.352

10.  Functional activity of the membrane-associated complement inhibitor CD59 in a pig-to-human in vitro model for hyperacute xenograft rejection.

Authors:  B Heckl-Ostreicher; R Binder; M Kirschfink
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.